- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06332755
Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109)
March 22, 2024 updated by: LG Chem
A Phase 1, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109 for the Treatment of Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose(RP2D) of LB-LR1109 and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109, and its impact on quality of life in participants with unresectable and metastatic nonsmall cell lung cancer(NSCLC), head and neck squamous cell carcinoma(HNSCC), renal cell carcinoma(RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
42
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Age ≥18 years old at the time of signing the ICF.
Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1,
- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.
- Participants who have metastatic disease which has progressed during or after all approved standard therapies or are intolerant to all approved therapies, or for which the participant refuses or is ineligible for standard therapy.
- Able to submit the most recently obtained archival tumor tissue
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
- Life expectancy ≥12 weeks.
- Participants with adequate organ function
- No potential for childbearing or agree to use adequate contraception
- Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.
Key Exclusion Criteria:
- Clinically significant cardiac disease or cardiac failure.
- Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease
- Participants with any concurrent active malignancies
- Prior LILRB or immunoglobulin-like transcript targeting therapy previously.
- History of life-threatening toxicity related to prior immune therapy
- Has not recovered to ≤ Grade 1 or baseline from AEs (except for toxicities not considered a safety risk such as alopecia, or asymptomatic laboratory abnormalities) due to prior therapy and/or complications from prior surgical intervention or any anti-cancer treatment before starting study treatment.
- Participants must not have an active, known, or suspected autoimmune disease.
- Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).
- Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.
- Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation
|
intravenous administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MTD and/or RP2D of LB-LR1109 in participants with advanced or metastatic solid tumors
Time Frame: through study completion, an average of 1year
|
Number of participants with dose-limiting toxicities (DLTs)
|
through study completion, an average of 1year
|
Incidence of Treatment-Emergent Adverse Events of LB-LR1109
Time Frame: through study completion, an average of 1year
|
Incidence, severity (assessed by NCI CTCAE v5.0), and causality of AEs
|
through study completion, an average of 1year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary efficacy of LB-LR1109
Time Frame: through study completion, an average of 1year
|
ORR(overall response rate) assessed by RECIST v1.1 (%)
|
through study completion, an average of 1year
|
Anti-tumor efficacy of LB-LR1109
Time Frame: through study completion, an average of 1year
|
PFS(Progression free survival) and OS(Overall survival) (months)
|
through study completion, an average of 1year
|
Pharmacokinetic profile of LB-LR1109
Time Frame: through study completion, an average of 1year
|
Cmax (Maximum serum drug concentration)
|
through study completion, an average of 1year
|
Characterize PK of LB-LR1109
Time Frame: through study completion, an average of 1year
|
Area under the concentration-time curve (AUC) 0-last
|
through study completion, an average of 1year
|
Immunogenicity of LB-LR1109
Time Frame: through study completion, an average of 1year
|
Number and percentage of participants with ADAs
|
through study completion, an average of 1year
|
Quality of life of participants
Time Frame: through study completion, an average of 1year
|
assessed by EORTC QLQ-C30
|
through study completion, an average of 1year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
November 1, 2025
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
February 16, 2024
First Submitted That Met QC Criteria
March 22, 2024
First Posted (Actual)
March 27, 2024
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 22, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Carcinoma, Squamous Cell
- Skin Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Melanoma
- Squamous Cell Carcinoma of Head and Neck
Other Study ID Numbers
- LG-LRCL001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma With Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial CarcinomaUnited States
Clinical Trials on LB-LR1109
-
LISCure BiosciencesCompletedRheumatoid Arthritis | Non-Alcoholic SteatohepatitisAustralia
-
Inova Health Care ServicesMedtronicRecruitingLeft Bundle-Branch Block | Heart Failure (HF) | Left Ventricular Ejection FractionUnited States
-
University of California, San DiegoCalifornia Institute for Regenerative Medicine (CIRM); Cystinosis Research...Active, not recruiting
-
Khon Kaen UniversityThai health promotion foundation.Terminated
-
Ain Shams UniversityCompleted
-
The Netherlands Cancer InstituteNot yet recruitingMetastatic Microsatellite-stable Colorectal Cancer
-
LB Pharmaceuticals Inc.Washington University School of MedicineCompletedSchizophreniaUnited States
-
LB Pharmaceuticals Inc.CompletedSchizophreniaUnited States
-
LB Pharmaceuticals Inc.Recruiting
-
Novartis PharmaceuticalsCompletedAsthmaGermany, United Kingdom